neutral sphingomyelinase activation associated factorGenealiases: FAN · GRAMD5
Q-omics provides the consensus-scored NSMAF profile across patient tissues and cancer cell-line models. NSMAF expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NSMAF is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, NSMAF RNA expression shows 20,368 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where NSMAF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NSMAF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NSMAF survival associations across molecular data types. NSMAF RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NSMAF RNA expression–survival associations across cancer types. High NSMAF expression shows unfavorable associations in UVM, LIHC, KIRP, KICH, MESO and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NSMAF RNA expression.
This table summarizes NSMAF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NSMAF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NSMAF shows higher tumor expression in HNSC, KIRP, KIRC, COAD, LIHC and LUSC. The HNSC box plot shows higher NSMAF RNA expression in tumor versus normal tissue (log2 FC = +0.884, t-test p < 0.001).
This table shows molecular features associated with NSMAF in patient tissues and cancer cell lines. In patient samples, NSMAF shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NSMAF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
